JD Health Likely to Maintain Solid Momentum in 2026 -- Market Talk

Dow Jones11-17

1057 GMT - JD Health International is likely to maintain solid momentum next year, Jefferies analysts say in a research note. The company's robust 3Q performance reinforces Jefferies' positive stance on its continued market share expansion, branded drug sales momentum and growing monetization from advertising and digital marketing, the analysts say. The company has raised its 2025's net profit guidance to 6.2 billion yuan from 5.6 billion yuan, the analysts note. "We expect a strong finish to 2025 and another solid year in 2026," the analysts say. Jefferies maintains a buy rating and a target price of HK$88.00. Shares last traded at HK$69.40. (tracy.qu@wsj.com)

(END) Dow Jones Newswires

November 17, 2025 05:57 ET (10:57 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment